Tricuspid / Pulmonary valve

Alessandro Sticchi and Luigi Biasco provide their take on the 1-year results of the CLASP TR study which were presented by Dr Adan Greenbaum, co-director of the Emory Structural Heart and Valve Center (Atlanta, GA) during the 2022 American College of Cardiology annual Congress held in Washington D.C.

An 81-year-old lady with past history of surgical aortic valve replacement followed by implantation of dual-chamber permanent pacemaker was admitted for recurrent episodes of right heart decompensations. The echocardiographic evaluation revealed massive TR and moderate primary MR due to a retracted posterior leaflet. What would be...

The authors hypothesized that disordered right ventricular to pulmonary artery (RV-PA) coupling may denote RV decompensation in patients undergoing transcatheter tricuspid valve repair (TTVR) that may correlate with poor clinical outcomes.

As the prognostic role of cardiohepatic syndrome (CHS) has not yet been evaluated, Stolz et al. in the present study assessed its impact on T-TEER outcomes.

A. Sticchi and J. Curio provide you with a summary of the studies that highlighted 2021 in the field of transcatheter tricuspid intervention: TRILUMINATE, CLASP TR EFS, EVOQUE TTVR, TRI-REPAIR, and more.

In this session, learn about the TricValve system in the treatment of severe TR and right heart disease, obtain insight from the experts with case scenarios, and understand how the TricValve Transcatheter Bicavel system can help patients with severe TR.

Alex Sticchi, interventional cardiologist, interviews Rebecca Hahn, Interventional Echocardiographer, about a recent State of the Art article about transcatheter treatment for tricuspid valve disease published in EuroIntervention.

They discuss the importance of starting with the classification of anatomy and that of secondary TR and identifying how clinical...

The PASCAL platform, comprising the PASCAL and PASCAL Ace implants, received its CE mark for TR in May 2020 and has been shown to be an effective and safe treatment option for patients with TR.3,4,6 Professor Jörg Hausleiter and Dr Mirjam Wild now describe their single-centre experience...

Imagine that you are faced with a patient with severe tricuspid regurgitation. You may ask yourself many questions, such as: what could be the prognosis of this patient? What is his/her life expectancy? Is he/she eligible for a particular treatment? What should be the appropriate timing...

Watch this PCR London Valves 2021 session to hear about the latest European guidelines on the management of tricuspid valve disease, understand the details behind these guidelines and how they compare with those elsewhere in the world, and, most importantly, find out how Heart Teams can translate...